MicuRx Pharmaceuticals closes RMB300m Series D

On August 5, MicuRx Pharmaceuticals, an antimicrobial drug development company announced the completion of a Series D financing round worth nearly 300 million yuan.
The round was led by Huagai Capital, and joined by Sinopharm-CICC and Zero2IPO Ventures.

On August 5, MicuRx Pharmaceuticals, an antimicrobial drug development company announced the completion of a Series D financing round worth nearly 300 million yuan.

The round was led by Huagai Capital, and joined by Sinopharm-CICC and Zero2IPO Ventures.

The proceeds will be used primarily to advance and expand clinical pipeline development, as well as full commercialization in China.

Dr. Yuan Zhengyu, Founder and CEO of the company, claims that in order to fully promote the independent commercialization of MicuRx Pharmaceuticals, a highly efficient and professional commercialization team will be set up.

Founded in 2007, MicuRx Pharmaceuticals is a developer of a biopharmaceutical platform designed to discover and develop antibiotics with improved safety profiles to improve the treatment of resistant bacterial infections.

The company’s biopharmaceutical platform uses compounds like contezolid (MRX-1), contezolid acefosamil (MRX-4) as well as next-generation oxazolidinones, which target methicillin resistant S. aureus (MRSA) to reduce hematological adverse events of this antibiotic class, enabling patients and healthcare institutions to avail safer and more convenient antibiotics to combat drug-resistant bacterial infections.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/08/07/micurx-pharmaceuticals-closes-rmb300m-series-d/.

Leave a Reply

Please Login to Comment